Skip to main content
OpenTrials
Completed

NCT Number: NCT01966081

AGARIC Case Control Study

The aim of the study is to establish the existence of a relationship between the dietary intake of polyunsaturated fatty acids (PUFA) and the risk of colorectal cancer in humans, using 2 reliable and complementary biomarkers: the fatty acid-composition of lipids of the abdominal subcutaneous adipose tissue and the fatty acid composition of erythrocyte phospholipids.

Completed

Looking for future studies?

Notify Me

Key information

Age range

45 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CHU Jean Minjoz, Besançon, France

Loading trial locations.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

CASES

  • Patients aged ≥ 45 years
  • with a first recently-diagnosed colorectal cancer
  • due to undergo elective surgical resection with curative intent (in practice, stage I, II, III or IV if there was only one hepatic nodule that was resected with curative intent) in one of the 5 following digestive surgery units: CHU de Dijon, CHU de Nancy, CHU de Strasbourg, CHU de Reims et CHU and Besançon.
  • who have given their informed consent

CONTROLS

  • Patients aged ≥ 45 years
  • due to undergo surgery for a benign abdominal disease (sigmoid diverticulitis, appendectomy, hiatal hernia …)
  • matched for abdominal site with cases for age (± 3 years), sex and hospital
  • Who have given their informed consent

Exclusion criteria

CASES

  • pre-operative anticancer treatment (chemo or radiotherapy)
  • existence of visceral metastases except a single hepatic nodule resected with curative intent
  • familial adenomatous polyposis and HNPCC syndrome (when suspected: inclusion after complementary tumor phenotype study: screening for microsatellite instability and/or immunohistochemistry study of the expression of DNA mismatch repair proteins.
  • known inflammatory disease of the intestine (ulcerative colitis, Crohn's disease)
  • personal history (recent or not) of colorectal cancer
  • emergency treatment for the presenting complication (perforation, occlusion…)
  • significant modification in dietary habits during the previous three months
  • other evolving neoplastic disease
  • psychic state incompatible with understanding the modalities and the aims of the study (notably patients under guardianship)
  • pregnant or breast-feeding women

CONTROLS

  • personal history of cancer or adenomatous colorectal polyps,
  • emergency intervention
  • known inflammatory disease of the intestine (ulcerative colitis, Crohn's disease)
  • personal history (recent or not) of colorectal cancer
  • emergency treatment for the presenting complication (perforation, occlusion…)
  • significant modification in dietary habits during the previous three months
  • evolving neoplastic disease
  • psychic state incompatible with understanding the modalities and the aims of the study (notably patients under guardianship)
  • pregnant or breast-feeding women

Treatment and study plan

blood sample

Other

tissue samples from abdominal subcutaneous adipose

Other

Primary outcomes

  1. Measure of polyunsaturated fatty acids in adipose tissue lipids.

    Time frame: baselines

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire Dijon

Other

Registry information

Official study title

Consumption of Fatty Acids, Metabolism of Adipose Tissue and Risk of Colorectal Cancer: AGARIC Case Control Study

Acronym: AGARIC

Important dates

Study start
2008
Primary completion
2011
Study completion
2011
First posted
Oct 21, 2013
Registry last updated
Feb 9, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.